Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma

European Journal of Haematology

Volumn 69, Issue 4, 2002, Pages 205-212

  Kuittinen, Outi ^a   Soini, Ylermi ^a   Turpeenniemi Hujanen, Taina ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Hodgkin's disease; Invasion; MMP 2; MMP 9; Neovascularization; Prognosis; Prognostic factors

Indexed keywords

GELATINASE A; GELATINASE B;

ANGIOGENESIS; ARTICLE; CANCER INVASION; CANCER STAGING; CELL INFILTRATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCLEROSIS; TUMOR VASCULARIZATION;

HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PROGNOSIS; REED-STERNBERG CELLS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 18744383031     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.02751.x     Document Type: Article

References (24)

1. Hayakawa T, Yamashita K. Tanzawa K, Uchijama E, Iwata K. Growth promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. FEBS Lett 1992;298:29-32.
2. Leslie NT, Mauch P, Hellman S. Stage IA and StIIB supradiaphragmatic Hodgkin's disease, long term survival and relapse frequency. Cancer 1985;55:2072-2078.
3. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995;7:728-735.
4. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor Batimastat (BB-94). Cancer Res 1996;56:2815-2822.
5. Väisänen A, Tuominen H, Kallioinen M, Turpeennienmi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996;180:283-289.
6. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;9:3064-3073.
7. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998;186:51-58.
8. Talvensaari-Mattila A, Pääkkö P. Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein a marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153-1162.
9. Kuittinen O, Savolainen EV, Koistinen P, Turpeenniemi-Hujanen T. Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML. Anticancer Res 1999;19:4395-4400.
10. Vacca A, Moretti S, Ribatti D, et al. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 1997;33:1685-1692.
11. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunology. J Immunol 1996;156:1-4.
12. Itoh T, Tanioka M, Yoshioda T, Nishimoto H, Itohara S. Reduced angiogenesis and tumour progression in gelatinase-A deficient mice. Cancer Res 1998;58:1048-1051.
13. Flavell JR, Baumforth KR, Williams DM, et al. Expression of the matrix metalloproteinase 9 in Hodgkin's lymphoma is independent of EBV status. Mol Pathol 2000;53:145-149.
14. Pich A, Stramignoni A, Navone R, Lega M, Gullino P. Angiogenic activity of hyperplastic and neoplastic lymph nodes. Tumori 1988;74:7-10.
15. Oelman E, Herbst H, Zuhlsdorf M, et al. Tissue inhibitor of metalloproteinase 1 is ah autocrine and paracrine survival factor, with additional immuneregulatory functions, expressed by Hodgkin/Reed-Sternberg cells. Blood 2002;99:258-267.
16. + cells and their transmigration through reconstituted basement membrane. Blood 1999;93:3379-3790.
17. Borregaard N, Sehested M, Nielsen BS, Sengelov H, Kjeldsen L. Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase as a marker of terminal neutrophil differentiation. Blood 1995;85:812-817.
18. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-4389.
19. Martin J, Eynstone L, Davies M, Steadman R. Induction of metalloproteinases by glomerular mesangial cells stimulated by proteins of extracellular matrix. J Am Soc Nephrol 2001;12:88-96.
20. Kossakowska AE, Urbanski SJ, Watson A, Hayden LJ, Edwards DR. Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res 1993;5:19-23.
21. Lalancette M, Aoudijt F. Potworowski EF, St-Pierre Y. Resistance of ICAM-deficient mice to metastasis overcome by increased aggressiveness of lymphoma cells. Blood 2000;95:314-319.
22. Kossakowska AE, Urbanski SJ, Edwards DR. Tissue inhibitor of metalloproteinases-1 (TIMP-I) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. A possible new growth factor in serum. Blood 1991;77:2474-2481.
23. Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998;8:171-177.
24. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001;61:237-242.